Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Talazoparib + ZEN-3694|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Talazoparib||Talzenna||BMN673||PARP Inhibitor (Pan) 29||Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations, and in combination with Xtandi (enzalutamide) in patients with homologous recombination repair gene (ATM, ATR, BRCA1/2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C)-mutated metastatic castration-resistant prostate cancer (FDA.gov).|
|ZEN-3694||ZEN003694|BETi ZEN-3694|ZEN3694|ZEN 3694||BET Inhibitor (Pan) 32||ZEN-3694 is a pan BET inhibitor that suppresses AR signaling, which potentially inhibits tumor progression (Cancer Res 2016;76(14 Suppl):Abstract nr LB-207, PMID: 32694156).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03901469||Phase II||Talazoparib + ZEN-3694||A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)||Recruiting||USA | ESP | BEL||1|
|NCT05327010||Phase II||Talazoparib + ZEN-3694||Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial||Recruiting||USA||0|
|NCT05071937||Phase II||Talazoparib + ZEN-3694||ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer||Recruiting||USA||0|